SG11201810123SA - Treatment of intrahepatic cholestatic diseases - Google Patents
Treatment of intrahepatic cholestatic diseasesInfo
- Publication number
- SG11201810123SA SG11201810123SA SG11201810123SA SG11201810123SA SG11201810123SA SG 11201810123S A SG11201810123S A SG 11201810123SA SG 11201810123S A SG11201810123S A SG 11201810123SA SG 11201810123S A SG11201810123S A SG 11201810123SA SG 11201810123S A SG11201810123S A SG 11201810123SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- newark
- pct
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Farming Of Fish And Shellfish (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662343688P | 2016-05-31 | 2016-05-31 | |
| PCT/US2017/029620 WO2017209865A1 (en) | 2016-05-31 | 2017-04-26 | Treatment of intrahepatic cholestatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810123SA true SG11201810123SA (en) | 2018-12-28 |
Family
ID=58699276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810123SA SG11201810123SA (en) | 2016-05-31 | 2017-04-26 | Treatment of intrahepatic cholestatic diseases |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10272058B2 (hu) |
| EP (1) | EP3463328B1 (hu) |
| JP (1) | JP7079735B2 (hu) |
| KR (1) | KR102408288B1 (hu) |
| CN (1) | CN109195594A (hu) |
| AU (1) | AU2017274293B2 (hu) |
| BR (1) | BR112018074147A2 (hu) |
| CA (1) | CA3024155C (hu) |
| DK (1) | DK3463328T3 (hu) |
| ES (1) | ES2921230T3 (hu) |
| HR (1) | HRP20220903T1 (hu) |
| HU (1) | HUE059838T2 (hu) |
| IL (1) | IL263372B2 (hu) |
| LT (1) | LT3463328T (hu) |
| MX (1) | MX2018014915A (hu) |
| NZ (1) | NZ748721A (hu) |
| PL (1) | PL3463328T3 (hu) |
| PT (1) | PT3463328T (hu) |
| RS (1) | RS63345B1 (hu) |
| RU (1) | RU2765460C2 (hu) |
| SG (1) | SG11201810123SA (hu) |
| SI (1) | SI3463328T1 (hu) |
| UA (1) | UA122719C2 (hu) |
| WO (1) | WO2017209865A1 (hu) |
| ZA (1) | ZA201808360B (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| MX367478B (es) | 2014-03-20 | 2019-08-23 | Cymaby Therapeutics Inc | Tratamiento de enfermedades colestasicas intrahepaticas. |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| US20200155650A1 (en) * | 2018-11-16 | 2020-05-21 | Cymabay Therapeutics, Inc. | Combination treatment of NAFLD and NASH |
| IL304873A (en) * | 2021-02-01 | 2023-10-01 | Cymabay Therapeutics Inc | Treatment of cholangiopathy with saldalafar |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6222025B1 (en) | 1995-03-06 | 2001-04-24 | Isis Pharmaceuticals, Inc. | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| BR9707529A (pt) | 1996-02-14 | 2000-01-04 | Isis Pharmaceuticals Inc | Oligunucleotìdeo especificamente hibridizável com dna ou rna. |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7981915B2 (en) | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| EP2100877B1 (en) | 2003-09-19 | 2012-01-25 | Janssen Pharmaceutica N.V. | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| EP2346498B1 (en) | 2008-10-17 | 2018-12-26 | Cymabay Therapeutics, Inc. | Methods of reducing small, dense ldl particles |
| NZ789295A (en) * | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| AU2011235301B2 (en) | 2010-03-30 | 2013-07-18 | Novartis Ag | Uses of DGAT1 inhibitors |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20150139987A1 (en) | 2013-11-20 | 2015-05-21 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| US20160279085A1 (en) | 2013-11-20 | 2016-09-29 | Cymabay Therapeutics, Inc. | Treatment of Severe Hyperlipidemia |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| MX367478B (es) | 2014-03-20 | 2019-08-23 | Cymaby Therapeutics Inc | Tratamiento de enfermedades colestasicas intrahepaticas. |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| WO2015200580A1 (en) | 2014-06-26 | 2015-12-30 | Cymabay Therapeutics, Inc. | Treatment of severe hypertriglyceridemia |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| PL3687523T3 (pl) | 2017-09-26 | 2022-02-21 | Cymabay Therapeutics, Inc. | Leczenie świądu cholestatycznego za pomocą seladelparu |
| US20200155650A1 (en) | 2018-11-16 | 2020-05-21 | Cymabay Therapeutics, Inc. | Combination treatment of NAFLD and NASH |
| MX2021005725A (es) | 2018-11-16 | 2021-07-21 | Cymabay Therapeutics Inc | Tratamiento de la obesidad y sus complicaciones. |
-
2017
- 2017-04-25 US US15/496,875 patent/US10272058B2/en active Active
- 2017-04-26 MX MX2018014915A patent/MX2018014915A/es unknown
- 2017-04-26 HU HUE17722943A patent/HUE059838T2/hu unknown
- 2017-04-26 KR KR1020187037704A patent/KR102408288B1/ko active IP Right Grant
- 2017-04-26 PL PL17722943.2T patent/PL3463328T3/pl unknown
- 2017-04-26 UA UAA201811776A patent/UA122719C2/uk unknown
- 2017-04-26 WO PCT/US2017/029620 patent/WO2017209865A1/en unknown
- 2017-04-26 SI SI201731175T patent/SI3463328T1/sl unknown
- 2017-04-26 NZ NZ748721A patent/NZ748721A/en unknown
- 2017-04-26 RS RS20220620A patent/RS63345B1/sr unknown
- 2017-04-26 RU RU2018146504A patent/RU2765460C2/ru active
- 2017-04-26 AU AU2017274293A patent/AU2017274293B2/en active Active
- 2017-04-26 JP JP2018562567A patent/JP7079735B2/ja active Active
- 2017-04-26 BR BR112018074147-7A patent/BR112018074147A2/pt not_active Application Discontinuation
- 2017-04-26 HR HRP20220903TT patent/HRP20220903T1/hr unknown
- 2017-04-26 PT PT177229432T patent/PT3463328T/pt unknown
- 2017-04-26 LT LTEPPCT/US2017/029620T patent/LT3463328T/lt unknown
- 2017-04-26 CA CA3024155A patent/CA3024155C/en active Active
- 2017-04-26 DK DK17722943.2T patent/DK3463328T3/da active
- 2017-04-26 CN CN201780033512.XA patent/CN109195594A/zh active Pending
- 2017-04-26 EP EP17722943.2A patent/EP3463328B1/en active Active
- 2017-04-26 ES ES17722943T patent/ES2921230T3/es active Active
- 2017-04-26 SG SG11201810123SA patent/SG11201810123SA/en unknown
-
2018
- 2018-11-29 IL IL263372A patent/IL263372B2/en unknown
- 2018-12-11 ZA ZA2018/08360A patent/ZA201808360B/en unknown
-
2019
- 2019-03-28 US US16/367,660 patent/US10478411B2/en active Active
- 2019-10-09 US US16/597,313 patent/US10813895B2/en active Active
-
2020
- 2020-09-18 US US17/024,971 patent/US11000494B2/en active Active
-
2021
- 2021-04-03 US US17/221,784 patent/US11596614B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies |